论文部分内容阅读
在斯德哥尔摩召开的“欧洲抗风湿病联盟”大会上,研究人员发布了由百时美施贵宝公司开发研究的生物药物CTLA41g(BMS188667)在治疗类风湿关节类方面的安全性、临床疗效和改善生活质量方面的临床数据。该药物Ⅱ期临床试验结果表明,CTLA41g作为第一个“协同刺激因子阻断剂”类新型治疗药物,对类风湿关节炎患者具有良好的耐受性和广泛的剂量范围。数据同时显示,接受CTLA41g治疗的患者生活质量得到极大改善。
At the European Alliance for Anti-Rheumatism in Stockholm, researchers released CTLA41g (BMS188667), a biologic drug developed by Bacerse Squibb, in the treatment of rheumatoid arthritis, its clinical efficacy and quality of life The clinical data. Phase II clinical trial results show that CTLA41g as the first “co-stimulating factor blocker” class of new drugs, rheumatoid arthritis patients with good tolerance and a wide range of doses. Data also showed that patients receiving CTLA41g treatment had a significant improvement in quality of life.